SCHEMBL25224282

SCHEMBL25224282

Cc1ccc(N)nc1-c1cc(F)nc(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.45
NOS2 P35228 2/20 0.45
NOS1 P29475 1/20 0.45
ADORA2B P29275 5/20 0.43
KMT2A Q03164 2/20 0.36
BACE1 P56817 5/20 0.35
NCK1 P16333 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
GAA P10253 1/20 0.35
TSHR P16473 1/20 0.35
AGTR1 P30556 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
CTSD P07339 1/20 0.35
ABL1 P00519 1/20 0.35
ADORA2A P29274 6/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26783358 0.78 CRHBP (0.46) KMT2AKDM4ENPC1GAATSHR
SCHEMBL13623157 0.77 ADORA2A (0.51) NOS3NOS2NOS1ADORA2BKMT2A
SCHEMBL26806827 0.75 NOS3 (0.50) NOS3NOS2NOS1ADORA2BKMT2A
SCHEMBL10066071 0.73 RAB9A (0.56) NOS3NOS2NOS1KMT2ABACE1
SCHEMBL16094239 0.70 ALDH1A1 (0.43) KMT2AKDM4ENPC1LMNATP53
SCHEMBL17609775 0.69 IDH1 (0.40) NOS3NOS2NOS1KMT2ABACE1
SCHEMBL25396981 0.69 MBNL1 (0.54) NOS3NOS2NOS1ADORA2BBACE1
SCHEMBL91461 0.69
SCHEMBL28663052 0.67 ADORA2A (0.54) ADORA2BKMT2ALMNATSHRABL1
SCHEMBL28231629 0.67 TP53 (0.43) NOS3NOS2NOS1KMT2ABACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119585242-A RAF kinase inhibitors and methods of use thereof 德西费拉制药有限责任公司 2025-03-07 CN disclosed
EP-4444430-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2024-10-16 EP disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 US disclosed
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-11-09 US disclosed
WO-2023108103-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357179-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF NOS3 3935/4885NOS2 4063/4885NOS1 4188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.